INBX

Inhibrx Biosciences Inc

May 20 • 04:00PM ET

110.01

+0.50 0.46 %

Healthcare • Biotechnology • USA • Small • NASD

| Held by: VTI XBI IWM VXF IWN IBB FYC VTWO FYX KOMP

Index	RUT	P/E	-	EPS (ttm)	-8.39	Insider Own	29.89%	Shs Outstand	14.61M	Perf Week	-6.73%
Market Cap	1.61B	Forward P/E	-	EPS next Y	-6.53	Insider Trans	0.00%	Shs Float	10.29M	Perf Month	30.84%
Enterprise Value	1.63B	PEG	-	EPS next Q	-2.28	Inst Own	77.10%	Short Float	26.57%	Perf Quarter	35.68%
Income	-130.19M	P/S	1241.52	EPS this Y	-2.16%	Inst Trans	29.21%	Short Ratio	7.01	Perf Half Y	42.22%
Sales	1.30M	P/B	-	EPS next Y	29.29%	ROA	-61.03%	Short Interest	2.73M	Perf YTD	39.25%
Book/sh	-1.44	P/C	9.98	EPS next 5Y	23.96%	ROE	-354.69%	52W High	155.29 -29.16%	Perf Year	741.70%
Cash/sh	11.02	P/FCF	-	EPS past 3/5Y	3.40% -	ROIC	-82.68%	52W Low	12.24 798.41%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-15.98% -	Gross Margin	-80.38%	Volatility	10.33% 13.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1256.32	EPS Y/Y TTM	-107.04%	Oper. Margin	-9465.46%	ATR (14)	12.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.46	Sales Y/Y TTM	550.00%	Profit Margin	-10014.23%	RSI (14)	49.94	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	6.46	EPS Q/Q	23.37%	SMA20	-10.38%	Beta	3.83	Target Price	277.50
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	19.12%	Rel Volume	1.10	Prev Close	109.51
Employees	110	LT Debt/Eq	-	Earnings	May 14 AMC	SMA200	62.14%	Avg Volume	390.01K	Price	110.01
IPO	May 29, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-28.36% -	Trades		Volume	428,162	Change	0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-26	Initiated	Stifel	Buy	$150
Jul-23-24	Initiated	JMP Securities	Mkt Perform

May-14-26 04:02PM	Inhibrx Reports First Quarter 2026 Financial Results (PR Newswire) -6.47%
May-11-26 08:26AM	This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know. (Barrons.com) -5.04%
08:00AM	Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy (PR Newswire)
06:00AM	Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive)
May-08-26 04:00PM	Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC (PR Newswire) +7.89%
04:05PM	Loading…
Apr-21-26 04:05PM	Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer (PR Newswire) +36.88%
Apr-20-26 05:03PM	Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer (PR Newswire) -6.62%
Apr-08-26 09:42AM	Coinbase downgraded, Deere upgraded: Wall Street's top analyst calls (The Fly) +7.67%
Mar-19-26 04:00PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results (PR Newswire) -5.56% -6.09%
Mar-02-26 04:00PM	Inhibrx Announces Participation in Upcoming Scientific Conference (PR Newswire)
Dec-28-25 10:05AM	Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts (Insider Monkey)
Dec-16-25 05:00PM	Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program (PR Newswire) +7.03%
Nov-14-25 06:00AM	Inhibrx Reports Third Quarter 2025 Financial Results (PR Newswire) +6.04%
Nov-04-25 04:01PM	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
Oct-24-25 07:40AM	Inhibrx Biosciences stock soars on chondrosarcoma Phase II victory (Clinical Trials Arena) +102.01%
04:05PM	Loading…
Oct-23-25 04:05PM	Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts (PR Newswire) -10.03%
Oct-22-25 04:01PM	Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts (PR Newswire) -15.99%
Aug-13-25 04:05PM	Inhibrx Reports Second Quarter 2025 Financial Results (PR Newswire) +7.53%
Jul-28-25 11:11AM	Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer (Insider Monkey) +6.46%
Jul-17-25 02:05PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily)
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Jul-10-25 02:24PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily)
May-14-25 04:05PM	Inhibrx Reports First Quarter 2025 Financial Results (PR Newswire) +10.89%
Apr-01-25 04:05PM	Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President (PR Newswire)
Mar-17-25 04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results (PR Newswire)
Jan-21-25 05:01PM	Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer (PR Newswire) +5.19%
Jan-13-25 04:15PM	Inhibrx Biosciences Announces Loan Agreement with Oxford Finance (PR Newswire) -6.60%
Nov-14-24 04:24PM	Inhibrx Biosciences Reports Third Quarter 2024 Financial Results (PR Newswire) -7.25%
Nov-04-24 04:00PM	Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation (PR Newswire)
Sep-13-24 01:55AM	Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX) (GuruFocus.com) +8.82%
06:54PM	Loading…
Aug-13-24 06:54PM	Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (PR Newswire)
May-24-24 04:00PM	Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi (PR Newswire)
May-10-24 06:36PM	Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off (PR Newswire)

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

FounderMr. Mark Paul Lappe

PresidentMr. David J. Matly M.B.A.

CPAMs. Kelly Devine Deck B.S.

Vice President of OperationsMs. Bonne Adams M.B.A.

M.B.A.Ms. Kate Burke CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VIKING GLOBAL INVESTORS LP	10% Owner	Oct 07 '25	Sale	32.25	350,000	11,287,500	67,018	Oct 09 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INBX

Inhibrx Biosciences Inc

Upgrade your Finviz experience